NCT00415103 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00415103/arm-group/c4ca4238a0b923820dcc509a6f75849b]
Palonosetron [clinicaltrials_resource:3d2ffe4560e1fca2894d475c0bb3079e]Aprepitant [clinicaltrials_resource:c4531599df03f82de769739bd65ef230]AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors [clinicaltrials:NCT00415103]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00415103 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00415103/arm-group/c4ca4238a0b923820dcc509a6f75849b]
Bio2RDF identifier
NCT00415103/arm-group/c4ca4238a0b923820dcc509a6f75849b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... ca4238a0b923820dcc509a6f75849b
description [clinicaltrials_vocabulary:description]
Aprepitant: 125 mg oral day 1, ...... every 48 horas starting day 1
identifier
clinicaltrials_resource:NCT00415103/arm-group/c4ca4238a0b923820dcc509a6f75849b
title
NCT00415103 arm group c4ca4238a0b923820dcc509a6f75849b
@en
type
label
NCT00415103 arm group c4ca4238 ...... a4238a0b923820dcc509a6f75849b]
@en